Brief: Gubra Announces Termination Of Collaboration With Bayer

Gubra A/S

23/08/2023 15:47

Aug 23 (Reuters) - Gubra A/S  GUBRA.CO :
    * ANNOUNCES TERMINATION OF COLLABORATION WITH BAYER
    * BAYER WILL RETURN ASSET FOLLOWING A PORTFOLIO REVIEW.
    * WILL ACTIVELY CONTINUE FURTHER DEVELOPMENT OF CARDIO-RENAL
METABOLIC PEPTIDE PROGRAMME
    * WE SEE GREAT POTENTIAL FOR DEVELOPING PROGRAMME WITHIN
'HEALTHY
WEIGHT LOSS,' ONE OF OTHER CORE AREAS AT GUBRA
    * EVALUATING WHETHER TO PROCEED INTO FURTHER DEVELOPMENT
OURSELVES
OR WITH A PARTNER
    * PEPTIDE PROGRAMME WAS LICENSED TO BAYER IN 2021, GUBRA WAS
ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND ROYALTIES WHICH WILL
NO LONGER BE CASE
    * WILL COMMUNICATE POTENTIAL OF FURTHER DEVELOPMENT OF THIS
METABOLIC PROGRAMME AT LATER STAGE WHEN DIFFERENT DEVELOPMENT
AND PARTNERSHIP OPTIONS HAVE BEEN THOROUGHLY EVALUATED

Source text for Eikon:  ID:nMFN4mJnwt 
Further company coverage:  GUBRA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))